Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Chase Investment Counsel Corp

Chase Investment Counsel Corp increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 2.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 93,601 shares of the biopharmaceutical company’s stock after purchasing an additional 2,264 shares during the period. Halozyme Therapeutics accounts for about 1.8% of Chase Investment Counsel Corp’s portfolio, making the stock its 20th largest position. Chase Investment Counsel Corp owned about 0.07% of Halozyme Therapeutics worth $5,357,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. TD Asset Management Inc boosted its position in Halozyme Therapeutics by 28.1% in the first quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock valued at $103,379,000 after buying an additional 557,350 shares during the last quarter. Congress Asset Management Co. increased its stake in shares of Halozyme Therapeutics by 446.5% in the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after acquiring an additional 1,988,238 shares during the period. Handelsbanken Fonder AB increased its stake in shares of Halozyme Therapeutics by 76.9% in the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock worth $112,715,000 after acquiring an additional 856,200 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Halozyme Therapeutics by 12.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after purchasing an additional 209,530 shares during the last quarter. Finally, Epoch Investment Partners Inc. grew its position in Halozyme Therapeutics by 23.3% during the 1st quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company’s stock worth $58,319,000 after purchasing an additional 270,579 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total transaction of $532,600.00. Following the completion of the sale, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $9,254,244.56. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 70,000 shares of company stock worth $4,042,500 in the last 90 days. Insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Stock Performance

HALO opened at $59.61 on Wednesday. The firm’s fifty day simple moving average is $56.53 and its two-hundred day simple moving average is $53.18. Halozyme Therapeutics, Inc. has a 52-week low of $33.15 and a 52-week high of $65.53. The company has a market cap of $7.58 billion, a price-to-earnings ratio of 19.74, a PEG ratio of 0.56 and a beta of 1.29. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. TD Cowen boosted their price objective on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. The Goldman Sachs Group upped their price objective on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research report on Monday, July 22nd. Wells Fargo & Company cut shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price objective for the stock from $58.00 to $62.00 in a research note on Monday, October 7th. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Finally, HC Wainwright lifted their price objective on shares of Halozyme Therapeutics from $65.00 to $68.00 and gave the company a “buy” rating in a report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $61.11.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.